In this study, we aimed to analyze the influence of tumoral Ang-2 level on lymph node involvement and retroperitoneal dissemination as well as its potential role as a biomarker to identify ovarian cancer patients who might benefit from bevacizumab maintenance therapy. This evidence concerns the gene ANGPT2 and ovarian carcinoma.